Poulin Y P
Department of Dermatology, Centre Hospitalier Universitaire de Québec, Canada.
Cutis. 1999 Jan;63(1):41-8.
A photographic tracking study was performed to facilitate a visual evaluation of the effect of treating psoriatic lesions in a clinical setting with tazarotene 0.05% gel, tazarotene 0.1% gel, tazarotene 0.1% gel plus mometasone furoate as needed for irritation, or tazarotene 0.1% gel plus mometasone furoate. Tazarotene was administered once daily in the evening, and mometasone furoate was administered once daily in the morning, for 12 weeks or until clearance if this occurred first. A total of twenty patients were enrolled in this open-label study. Rates of treatment success (50% or greater improvement in psoriasis) were higher with tazarotene 0.1% monotherapy compared with tazarotene 0.05% monotherapy, and were higher still when tazarotene was used in combination with mometasone furoate. Concurrent use of this steroid also enhanced speed of efficacy, patient satisfaction, and tolerability. Furthermore, long periods of remission were achieved in patients treated with combination tazarotene plus corticosteroid therapy. These findings suggest that tazarotene plus a mid-potency topical corticosteroid is a valuable first-line treatment option for stable plaque psoriasis.
进行了一项摄影跟踪研究，以利于在临床环境中对使用0.05%他扎罗汀凝胶、0.1%他扎罗汀凝胶、根据刺激情况必要时加用糠酸莫米松的0.1%他扎罗汀凝胶或0.1%他扎罗汀凝胶加糠酸莫米松治疗银屑病皮损的效果进行视觉评估。他扎罗汀于每晚给药一次，糠酸莫米松于每天早晨给药一次，持续12周，或若先出现皮损清除则提前停药。共有20名患者纳入了这项开放标签研究。与0.05%他扎罗汀单药治疗相比，0.1%他扎罗汀单药治疗的治疗成功率（银屑病改善50%或更高）更高，而当他扎罗汀与糠酸莫米松联合使用时治疗成功率更高。同时使用这种类固醇还提高了疗效速度、患者满意度和耐受性。此外，接受他扎罗汀加皮质类固醇联合治疗的患者实现了长时间的缓解。这些发现表明，他扎罗汀加中效外用皮质类固醇是稳定斑块状银屑病的一种有价值的一线治疗选择。
